Enveda Biosciences Announces Oversubscribed Series B1 Bringing … – Business Wire
New investor Kinnevik led the round with outsized participation from current investors
The company is advancing multiple candidates toward the clinic and scaling the platform
BOULDER, Colo.–(BUSINESS WIRE)–Enveda Biosciences today announced that it has closed an additional $51 million equity financing to add to the $68 million Series B announced in December 2022. Kinnevik led the Series B1 round, which also included participation by new investor Henry R. Kravis, the Co-Founder and Co-Executive Chairman of KKR. The round included strong participation from Enveda’s current major investors, including FPV, True Ventures, Dimension, and Wireframe.
Enveda’s use of large language models, metabolomics, and robotics to search nature’s chemical space unlocks one of the most validated approaches to drug discovery – Christian Scherrer, Investment Director at Kinnevik
Enveda is a drug discovery and development company using the latest AI-powered technologies to uncover the ancient…
The post Enveda Biosciences Announces Oversubscribed Series B1 Bringing … – Business Wire first appeared on SEO, Marketing and Social News | OneSEOCompany.com.
source: https://news.oneseocompany.com/2023/04/20/enveda-biosciences-announces-oversubscribed-series-b1-bringing-business-wire_2023042043777.html
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.